Treatment of intracranial alphavirus infections in mice by a combination of specific antibodies and an interferon inducer

D. H. Coppenhaver, I. P. Singh, M. Sarzotti, H. B. Levy, S. Baron

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Finding an effective treatment for viral infections that cause encephalitis remains an important problem. A model of human alphavirus infections, Semliki Forest virus, causes lethal encephalitis in weanling mice. Mice arc viremic within 24 hr of an intraperitoneal challenge with the equivalent of three 75% lethal doses of Semliki Forest virus. Virus reaches the brain by 48 hr, and mortality results in all mice in 5-7 days. Introduction of virus intracranially accelerates the course of the infection. Neither anti Semliki Forest virus hyperimmune serum nor the potent interferon inducer poly I:CLC given intraperitoneally are protective when used therapeutically after an intracranial virus infection, but a combination of 1,000 U hyperimmune serum and 80 μg/mouse of poly I:CLC results in a 50% survival rate. This combination treatment of intracranial Semliki Forest virus infection eliminates detectable viremia and reduces virus load in the brain over the course of the infection. These data show that when combined, specific antibody and an interferon inducer can interact synergistically to protect mice from alphavirus infections of the central nervous system even when given after the virus is replicating in the target organ.

Original languageEnglish (US)
Pages (from-to)34-40
Number of pages7
JournalAmerican Journal of Tropical Medicine and Hygiene
Volume52
Issue number1
StatePublished - 1995

Fingerprint

Alphavirus Infections
Interferon Inducers
Semliki forest virus
Virus Diseases
Poly I
Antibodies
Viruses
Encephalitis
Viremia
Brain
Infection
Serum
Survival Rate
Central Nervous System
Mortality

ASJC Scopus subject areas

  • Parasitology
  • Infectious Diseases

Cite this

Treatment of intracranial alphavirus infections in mice by a combination of specific antibodies and an interferon inducer. / Coppenhaver, D. H.; Singh, I. P.; Sarzotti, M.; Levy, H. B.; Baron, S.

In: American Journal of Tropical Medicine and Hygiene, Vol. 52, No. 1, 1995, p. 34-40.

Research output: Contribution to journalArticle

Coppenhaver, D. H. ; Singh, I. P. ; Sarzotti, M. ; Levy, H. B. ; Baron, S. / Treatment of intracranial alphavirus infections in mice by a combination of specific antibodies and an interferon inducer. In: American Journal of Tropical Medicine and Hygiene. 1995 ; Vol. 52, No. 1. pp. 34-40.
@article{b20f3cb1140d46b39b788df93dfb7396,
title = "Treatment of intracranial alphavirus infections in mice by a combination of specific antibodies and an interferon inducer",
abstract = "Finding an effective treatment for viral infections that cause encephalitis remains an important problem. A model of human alphavirus infections, Semliki Forest virus, causes lethal encephalitis in weanling mice. Mice arc viremic within 24 hr of an intraperitoneal challenge with the equivalent of three 75{\%} lethal doses of Semliki Forest virus. Virus reaches the brain by 48 hr, and mortality results in all mice in 5-7 days. Introduction of virus intracranially accelerates the course of the infection. Neither anti Semliki Forest virus hyperimmune serum nor the potent interferon inducer poly I:CLC given intraperitoneally are protective when used therapeutically after an intracranial virus infection, but a combination of 1,000 U hyperimmune serum and 80 μg/mouse of poly I:CLC results in a 50{\%} survival rate. This combination treatment of intracranial Semliki Forest virus infection eliminates detectable viremia and reduces virus load in the brain over the course of the infection. These data show that when combined, specific antibody and an interferon inducer can interact synergistically to protect mice from alphavirus infections of the central nervous system even when given after the virus is replicating in the target organ.",
author = "Coppenhaver, {D. H.} and Singh, {I. P.} and M. Sarzotti and Levy, {H. B.} and S. Baron",
year = "1995",
language = "English (US)",
volume = "52",
pages = "34--40",
journal = "American Journal of Tropical Medicine and Hygiene",
issn = "0002-9637",
publisher = "American Society of Tropical Medicine and Hygiene",
number = "1",

}

TY - JOUR

T1 - Treatment of intracranial alphavirus infections in mice by a combination of specific antibodies and an interferon inducer

AU - Coppenhaver, D. H.

AU - Singh, I. P.

AU - Sarzotti, M.

AU - Levy, H. B.

AU - Baron, S.

PY - 1995

Y1 - 1995

N2 - Finding an effective treatment for viral infections that cause encephalitis remains an important problem. A model of human alphavirus infections, Semliki Forest virus, causes lethal encephalitis in weanling mice. Mice arc viremic within 24 hr of an intraperitoneal challenge with the equivalent of three 75% lethal doses of Semliki Forest virus. Virus reaches the brain by 48 hr, and mortality results in all mice in 5-7 days. Introduction of virus intracranially accelerates the course of the infection. Neither anti Semliki Forest virus hyperimmune serum nor the potent interferon inducer poly I:CLC given intraperitoneally are protective when used therapeutically after an intracranial virus infection, but a combination of 1,000 U hyperimmune serum and 80 μg/mouse of poly I:CLC results in a 50% survival rate. This combination treatment of intracranial Semliki Forest virus infection eliminates detectable viremia and reduces virus load in the brain over the course of the infection. These data show that when combined, specific antibody and an interferon inducer can interact synergistically to protect mice from alphavirus infections of the central nervous system even when given after the virus is replicating in the target organ.

AB - Finding an effective treatment for viral infections that cause encephalitis remains an important problem. A model of human alphavirus infections, Semliki Forest virus, causes lethal encephalitis in weanling mice. Mice arc viremic within 24 hr of an intraperitoneal challenge with the equivalent of three 75% lethal doses of Semliki Forest virus. Virus reaches the brain by 48 hr, and mortality results in all mice in 5-7 days. Introduction of virus intracranially accelerates the course of the infection. Neither anti Semliki Forest virus hyperimmune serum nor the potent interferon inducer poly I:CLC given intraperitoneally are protective when used therapeutically after an intracranial virus infection, but a combination of 1,000 U hyperimmune serum and 80 μg/mouse of poly I:CLC results in a 50% survival rate. This combination treatment of intracranial Semliki Forest virus infection eliminates detectable viremia and reduces virus load in the brain over the course of the infection. These data show that when combined, specific antibody and an interferon inducer can interact synergistically to protect mice from alphavirus infections of the central nervous system even when given after the virus is replicating in the target organ.

UR - http://www.scopus.com/inward/record.url?scp=0028931769&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028931769&partnerID=8YFLogxK

M3 - Article

VL - 52

SP - 34

EP - 40

JO - American Journal of Tropical Medicine and Hygiene

JF - American Journal of Tropical Medicine and Hygiene

SN - 0002-9637

IS - 1

ER -